60770-60-7

Usage

Uses

Used in Medicinal Chemistry and Drug Development:
5-fluoro-2,3-dihydrobenzofuran-3-ol is used as a pharmaceutical intermediate for the development of new drugs, leveraging its potential pharmacological properties. Its unique structure allows it to interact with biological targets, potentially leading to the discovery of novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 5-fluoro-2,3-dihydrobenzofuran-3-ol is employed as a building block for the creation of more complex organic molecules. Its presence in these molecules can impart specific chemical and biological properties, making it a valuable component in the synthesis of various compounds.
Used in Pharmaceutical Industry:
5-fluoro-2,3-dihydrobenzofuran-3-ol is used as a key component in the formulation of pharmaceutical products. Its incorporation into drug molecules can enhance their efficacy, selectivity, and pharmacokinetic properties, contributing to the development of more effective treatments for various diseases.
Used in Research and Development:
5-fluoro-2,3-dihydrobenzofuran-3-ol is utilized in research laboratories for the investigation of its potential applications in various industries. Scientists are exploring its chemical properties, reactivity, and interactions with biological systems to uncover new uses and optimize its performance in different applications.
Used in Chemical Industry:
In the chemical industry, 5-fluoro-2,3-dihydrobenzofuran-3-ol may be employed as a specialty chemical for specific applications. Its unique structure and properties can be harnessed to develop new materials, catalysts, or other products with tailored characteristics for use in various sectors.

Upstream product

• 347-54-6 5-fluoro-2-hydroxybenzaldehyde 
• 1774-47-6 trimethylsulfoxonium iodide 
• 877263-50-8 C₁₁H₁₅FO₂Si 

Downstream Products

• 1373126-71-6 C₂₀H₁₈FN₃O₃ 
• 885280-83-1 C₈H₈FNO 

Relevant academic research and scientific papers

Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators

We report the discovery and optimization of a novel series of dihydrobenzofuran amides as γ-secretase modulators (GSMs). Strategies for aligning in vitro potency with drug-like physicochemical properties and good microsomal stability while avoiding P-gp mediated efflux are discussed. Lead compounds such as 35 and 43 have moderate to good in vitro potency and excellent selectivity against Notch. Good oral bioavailability was achieved as well as robust brain Aβ42 lowering activity at 100 mg/kg po dose.

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle optionally substituted with substituents (1 to 4 in number) as defined in R14; with R1, R2, R3, R4, R5, R6, R7, R8, and R14 defined herein.